WIN-Partners (3183) FY2027 Q1 Earnings Report

Quick View

Executive Summary

Revenue increased but earnings declined. While demand remained firm, a decline in the gross margin and an increase in SG&A expenses pressured margins. Revenue increased to ¥239.7B (¥220.8B in the same period of the previous year, YoY +8.5%), while Operating Income declined to ¥6.0B (¥7.0B in the same period of the previous year, YoY -15.0%), Ordinary Income declined to ¥6.1B (¥7.1B in the same period of the previous year, YoY -13.4%), and Net Income declined to ¥4.0B (¥4.8B in the same period of the previous year, YoY -16.3%). The primary reasons for the earnings decline despite higher revenue were the decrease in the gross margin to 11.0% (11.7% in the same period of the previous year) and the increase in the SG&A ratio to 8.5%.

Factors Driving Changes in Performance

【Revenue】Revenue increased to ¥239.7B, representing a year-on-year increase of +8.5%. The Company operates in a single segment, the Medical Equipment Sales Business, and does not disclose results by segment. Progress against the full-year plan of ¥1000.0B was 24.0%, broadly close to the standard quarterly progress level (approximately 25%).

【Profit and Loss】Cost of sales increased at a faster pace than Revenue to ¥213.3B, and the gross margin declined by -0.7pt to 11.0% (11.7% in the same period of the previous year). SG&A expenses increased to ¥20.5B (¥18.8B in the same period of the previous year), while the SG&A ratio rose slightly to 8.5% (8.5% in the same period of the previous year), reflecting an increase in expenses exceeding revenue growth. As a result, Operating Income declined to ¥6.0B (YoY -15.0%), and the Operating Margin narrowed by -0.7pt to 2.5% (3.2% in the same period of the previous year). Ordinary Income was ¥6.1B (YoY -13.4%), and Net Income was ¥4.0B (YoY -16.3%), resulting in higher revenue but lower earnings.

Key Financial Metrics

【Profitability】The Operating Margin declined to 2.5% (3.2% in the same period of the previous year), the Net Profit Margin declined to 1.7% (2.2% in the same period of the previous year), and the gross margin declined to 11.0% (11.7% in the same period of the previous year), with all metrics decreasing year on year.【Cash Quality】Comprehensive Income was ¥4.0B, broadly in line with Net Income of ¥4.0B. The impact of valuation differences on other securities and adjustments related to retirement benefits remained limited, with no significant divergence attributable to accrual factors.【Investment Efficiency】ROE was 1.8%, consistent with the decomposition of Net Profit Margin of 1.7% × total asset turnover of 0.48 × financial leverage of 2.24. EPS was ¥14.64 (¥16.98 in the same period of the previous year), and BPS was ¥807.38 (¥846.95 in the same period of the previous year), with both below the previous year’s levels.【Financial Soundness】The Equity Ratio was 44.7% (46.0% in the same period of the previous year), the current ratio was 163.8%, and the quick ratio was 129.1%, indicating a certain degree of short-term financial flexibility. Net assets were ¥222.0B, down ¥10.9B from ¥232.9B at the end of the previous fiscal year, while retained earnings also declined to ¥213.0B (¥223.8B at the end of the previous fiscal year).

Cash Flow Analysis

As no cash flow statement has been disclosed, the trend in funds can be assessed based on changes in the balance sheet. Cash and deposits were ¥150.0B, down ¥9.3B from ¥159.3B at the end of the previous fiscal year. Accounts receivable were ¥178.9B, down ¥6.4B from ¥185.3B at the end of the previous fiscal year, while accounts payable were ¥198.1B, up ¥1.7B from ¥196.4B, both of which appear to have contributed positively to cash. On the other hand, inventories were ¥44.6B, up ¥5.4B from ¥39.2B at the end of the previous fiscal year, while income taxes payable were ¥23.4B, down ¥54.5B from ¥77.9B at the end of the previous fiscal year. The buildup of inventory and payment of income taxes may have put pressure on funds. Overall, the decrease in cash and deposits during the period is considered to have resulted from funding requirements, including increased inventories and tax payments, exceeding the ¥4.0B in Net Income recorded.

Quality of Earnings

Non-operating income was ¥0.2B, primarily attributable to interest income of ¥0.16B, and was almost offset by non-operating expenses of ¥0.0B, resulting in a limited impact on Ordinary Income. Extraordinary income was a modest ¥0.03B, consisting of a gain on the sale of fixed assets, and the impact of temporary factors on performance can therefore be considered limited. The ¥2.1B difference between Ordinary Income of ¥6.1B and Net Income of ¥4.0B was attributable to income taxes of ¥2.1B. The effective tax rate increased to 34.7% (32.3% in the same period of the previous year), and the higher tax burden contributed to the lack of growth in Net Income. Comprehensive Income of ¥4.0B was broadly in line with Net Income of ¥4.0B. Changes in valuation differences on other securities and adjustments related to retirement benefits remained limited, and no factor that significantly distorted earnings quality was identified.

Earnings Forecast and Guidance

Progress against the full-year plan (Revenue of ¥1000.0B, Operating Income of ¥33.5B, Ordinary Income of ¥33.8B, and Net Income of ¥22.1B) was 24.0% for Revenue, 17.9% for Operating Income, 18.1% for Ordinary Income, and 18.2% for Net Income. Revenue was close to the standard quarterly progress level (approximately 25%), but all profit metrics were below that level, reflecting the lack of operating leverage due to the lower gross margin and higher SG&A expenses. The full-year plan calls for higher revenue and higher earnings year on year (Operating Income YoY +10.9%), but earnings declined in the current period. Margin recovery toward the second half of the fiscal year will therefore be the key to achieving the plan. There were no revisions to the earnings or dividend forecasts during the quarter.

Shareholder Returns

The dividend forecast is ¥55.00 per share. Based on the weighted-average number of shares outstanding during the period of 27,498,171 shares, the total annual dividend is estimated at approximately ¥1.5B. The Payout Ratio against the full-year Net Income plan of ¥22.1B is approximately 68.4%, and would be even higher if based on current-period Net Income of ¥4.0B. Cash and deposits of ¥150.0B and an Equity Ratio of 44.7% provide support for continued dividend payments; however, the Payout Ratio itself is relatively high compared with the level of earnings, warranting monitoring in light of future earnings trends.

Risk Factors

1. Profitability Decline Risk: The gross margin declined to 11.0% (11.7% in the same period of the previous year), and the Operating Margin declined to 2.5% (3.2% in the same period of the previous year). If this trend continues, it may affect achievement of the full-year plan, equivalent to an Operating Margin of 3.35%.

2. Working Capital Expansion Risk: Inventories increased to ¥44.6B (+¥5.4B from ¥39.2B at the end of the previous fiscal year), and together with accounts receivable of ¥178.9B, may result in increased funds being tied up.

3. Tax Burden Volatility Risk: The effective tax rate increased to 34.7% in the current period (32.3% in the same period of the previous year), and fluctuations in the tax burden may become a factor weighing on Net Income.

Industry Benchmark (For Reference; Company Research)

Industry Benchmark (trading)

Profitability and Returns

The Company’s profitability metrics are below the industry median and are positioned within the lower range.

Growth and Capital Efficiency

The Revenue Growth Rate is significantly above the industry median and is positioned within the top range.

※Source: Company research

Key Points from the Earnings Results

1. Despite higher revenue (+8.5%), the Operating Margin declined to 2.5% (3.2% in the same period of the previous year), primarily due to deterioration in the gross margin (11.0%, compared with 11.7% in the same period of the previous year). Progress of Operating Income against the full-year plan was 17.9%, below the standard level (approximately 25%), making margin recovery in the second half of the fiscal year the key to achieving the plan.

2. Inventories increased by +¥5.4B from the end of the previous fiscal year, and together with accounts receivable of ¥178.9B, create a structure in which funds are likely to become tied up. Trends in inventory and accounts receivable management will be factors affecting future cash generation capacity.

3. The Payout Ratio is approximately 68% based on the full-year plan. Although it is supported by cash and deposits of ¥150.0B, the Company’s return stance is relatively high compared with the current period’s earnings level.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson type with an explicit five-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥800–¥845 at a ±1% change in the Cost of Equity, and ¥822–¥822 at a ±0.1 change in ω.

Notes:

• Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).

(Calculation model: Residual Income Model / Interest Rate Reference Month: 2026-06 / This value does not predict or guarantee future share prices)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own responsibility, and after consulting a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a mixed start: revenue expanded, but profit declined materially as gross-margin compression and cost growth outweighed higher sales. Revenue rose 8.5% YoY to ¥23.97bn. Gross profit increased only 2.6% YoY to ¥2.64bn, materially lagging revenue growth. The gross profit margin declined 64bp YoY to 11.0% from 11.7%. SG&A expenses increased 9.7% YoY to ¥2.05bn, slightly exceeding revenue growth. Consequently, operating income fell 15.0% YoY to ¥596m. The operating margin compressed 69bp YoY to 2.5% from 3.2%. Ordinary income declined 13.4% YoY to ¥613m, supported modestly by ¥16m of interest income. Net income decreased 16.3% YoY to ¥403m, and basic EPS declined to ¥14.64 from ¥16.98. The net profit margin contracted 50bp YoY to 1.7% from 2.2%. Profit before tax included a small ¥3m gain on sale of non-current assets, which was immaterial to the earnings trend. The effective tax rate was 34.6%, leaving a tax burden of 0.653 and contributing to the gap between pre-tax profit and net income. The annualized ROE was 7.2%, below the 8% benchmark and reflects modest margins combined with balance-sheet leverage. Liquidity remains sound, with a 163.8% current ratio, a 146.3% quick ratio, and ¥15.00bn of cash and deposits. Management maintained its full-year forecast, but Q1 progress was 24.0% for revenue, 17.8% for operating income, and 18.2% for net income, indicating that delivery of the full-year profit plan requires a substantial acceleration in subsequent quarters. The principal near-term issue is therefore whether the company can restore gross margin and contain SG&A growth while sustaining revenue momentum in its medical-device sales business.

Profitability Analysis

Annualized DuPont ROE was 7.2%, comprising a 1.7% net profit margin, 1.932x asset turnover, and 2.24x financial leverage. The weakest component is the net margin, which is below the 3% concern threshold and declined from an estimated 2.2% in the prior-year quarter. Asset turnover is comparatively robust for a distribution-led business and reflects the company’s high revenue base relative to total assets. Financial leverage supports shareholder returns, but it does not fully offset the low-margin business model. The principal YoY deterioration came from profitability rather than asset utilization: gross margin fell 64bp and operating margin fell 69bp. Revenue growth of 8.5% did not convert into operating-profit growth because cost of sales increased 9.3%, faster than sales. SG&A increased 9.7%, also exceeding revenue growth, and the SG&A-to-sales ratio rose modestly to 8.5% from 8.5% in the prior-year quarter. This negative operating leverage is the central earnings issue in Q1. EBIT margin was 2.5%, explicitly below the 5% operating-efficiency benchmark; in a medical-device distributor, low margins are structurally more common than in manufacturing, but further compression materially reduces earnings resilience. The 11.0% gross margin is also below the 20% generic benchmark and was the immediate cause of weaker profit conversion. Interest income of ¥16m was small relative to revenue and did not meaningfully alter recurring profitability. The small extraordinary gain of ¥3m was non-recurring but immaterial. Sustained improvement in ROE will require margin recovery or better SG&A absorption, rather than additional financial leverage.

Growth Assessment

Top-line growth was solid, with Q1 revenue up 8.5% YoY to ¥23.97bn. However, gross profit grew just 2.6% YoY and operating income fell 15.0% YoY, demonstrating weak profit conversion from incremental sales. The full-year revenue forecast is ¥100.0bn, implying 10.6% YoY growth, and Q1 progress of 24.0% is close to the standard 25% first-quarter pace. The full-year operating-income forecast is ¥3.35bn, implying 10.9% YoY growth, but Q1 progress of 17.8% is 7.2 percentage points below the standard 25% pace. Full-year net income is forecast at ¥2.21bn, with Q1 progress of 18.2%, also requiring stronger earnings conversion in later quarters. The deviation from standard Q1 profit progress is below the 10 percentage-point threshold, but the gap remains notable because Q1 operating income fell despite sales growth. Management made no revision to either earnings guidance or dividend guidance. The business operates as a single medical-device sales segment, so earnings recovery depends on the group’s consolidated ability to improve pricing, product mix, purchasing conditions, and operating-cost absorption. Receivables declined 3.7% YoY while sales rose, indicating that receivable expansion did not fund reported growth. Inventory increased 13.8% YoY to ¥4.46bn, faster than revenue growth, and should be monitored for its relationship to anticipated sales demand and gross-margin performance.

Financial Health

Liquidity is healthy. Current assets of ¥41.74bn exceeded current liabilities of ¥25.48bn, producing a current ratio of 163.8% and working capital of ¥16.26bn. The quick ratio was also strong at 146.3%, indicating that liquidity is not dependent on inventory liquidation. Cash and deposits totaled ¥15.00bn, equivalent to 30.2% of total assets. Trade receivables were ¥17.89bn and inventories were ¥4.46bn, together representing the main operating working-capital commitments. Current liabilities are dominated by trade payables of ¥19.81bn and electronically recorded obligations of ¥3.36bn, which is broadly consistent with a distribution business funded in part through supplier credit. Current assets exceed current liabilities by ¥16.26bn, limiting near-term maturity-mismatch risk. Total liabilities were ¥27.43bn, or 55.3% of total assets, while total equity was ¥22.20bn and the equity ratio was 44.7%. The reported debt-to-equity ratio was 1.24x, below the 2.0x aggressive-financing warning threshold. Non-current liabilities were limited at ¥1.96bn, including a ¥1.17bn net defined-benefit liability. Intangible assets represented only 2.1% of total assets, indicating limited balance-sheet concentration in acquired intangible value. Total equity declined ¥1.09bn YoY, and book value per share declined to ¥807.38 from ¥846.95; capital preservation and earnings recovery are therefore relevant to future per-share value creation.

Cash Flow Quality

Dividend Sustainability

The full-year dividend forecast is ¥55 per share and was maintained. Against forecast EPS of ¥80.37, the implied dividend payout ratio is approximately 68.4%. This is above the 60% sustainability benchmark but remains below 100%, indicating that the forecast dividend is covered by forecast accounting earnings. The relatively elevated payout leaves a narrower earnings-retention buffer if profit recovery is delayed. Treasury shares amount to 3.01m shares, or approximately 9.9% of issued shares, but no current-period share-repurchase amount is provided; therefore, a total return ratio cannot be assessed. The maintained dividend outlook depends principally on achieving the ¥2.21bn full-year net-income forecast and protecting the company’s solid liquidity position.

Risk Assessment

Business risks include Margin risk: gross margin declined 64bp YoY to 11.0%, while cost of sales grew 9.3% against 8.5% sales growth. In the low-margin medical-device distribution model, modest changes in supplier terms, sales mix, or selling prices can have an outsized effect on operating income., Operating-efficiency risk: EBIT margin was 2.5%, below the 5% benchmark, and SG&A increased 9.7% YoY, faster than revenue. The low operating margin reduces the buffer against a slowdown in procedure volumes or pricing pressure., Medical-device industry risk: hospital capital-spending patterns, procedure volumes, reimbursement revisions, regulatory requirements, and procurement policies can affect demand, product mix, and distributor margins., Inventory risk: inventories increased 13.8% YoY to ¥4.46bn, outpacing sales growth. If demand or product mix changes, inventory turnover and realized margins could weaken., Receivables-management risk: annualized DSO was 68 days, above the 60-day quality-alert threshold. This is a concern because a sizable portion of assets is tied to customer receivables, although trade receivables declined 3.7% YoY and the ratio should be assessed in the context of hospital and healthcare-customer payment cycles..

Financial risks include Equity declined 4.7% YoY to ¥22.20bn, lowering book value per share to ¥807.38 from ¥846.95., The reported debt-to-equity ratio of 1.24x is manageable and below the 2.0x warning threshold, but financial leverage of 2.24x means that sustained low margins would constrain returns on equity., The forecast dividend payout ratio of approximately 68.4% is above the 60% benchmark, reducing flexibility should full-year earnings fall short of plan., The net defined-benefit liability was ¥1.17bn, representing a continuing long-term obligation..

Key concerns include Highest priority: restoring profit conversion, as operating income fell 15.0% despite 8.5% revenue growth., High priority: confirming that inventory growth reflects demand and does not signal slower-moving product or weaker future gross margins., High priority: reducing or stabilizing DSO from the 68-day level while preserving customer relationships and sales growth., Medium priority: achieving the full-year operating-income forecast requires a pronounced improvement from the 17.8% Q1 progress rate., Quality-alert context: the 2.5% EBIT margin and 11.0% gross margin are low, though lower margins are more typical for a medical-device distributor than for a manufacturer; the YoY decline, rather than the absolute level alone, is the more adverse development..

Investment Implications

Key takeaways include Revenue momentum remained positive, with sales up 8.5% YoY to ¥23.97bn., Profitability deteriorated: gross margin fell to 11.0%, operating margin fell to 2.5%, and net income declined 16.3% YoY., The annualized 7.2% ROE was supported by 1.932x asset turnover and 2.24x financial leverage, but constrained by a 1.7% net margin., Liquidity is strong, with current and quick ratios above 1.4x and cash of ¥15.00bn., The unchanged full-year plan requires later-quarter improvement in gross margin and SG&A absorption..

Metrics to watch include Gross profit margin and operating margin versus the Q1 levels of 11.0% and 2.5%, SG&A growth relative to revenue growth, Progress toward the ¥3.35bn full-year operating-income forecast, Inventory growth and inventory turnover, Annualized DSO, currently 68 days, Dividend coverage relative to the implied 68.4% forecast payout ratio, Equity and book value per share trends.

Regarding relative positioning, The company has the balance-sheet liquidity and asset-turnover profile typical of a financially sound distributor, but its Q1 profitability is weak versus broad profitability benchmarks. Relative performance is therefore likely to be determined by its ability to preserve medical-device distribution margins and generate operating leverage, rather than by balance-sheet repair.